Hanall Biopharma Co., Ltd.

As of June 30, 2026, Hanall Biopharma Co., Ltd. carries a market capitalization of 3.17T, placing it among publicly traded companies globally. Its enterprise value stands at 3.18T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Hanall Biopharma Co., Ltd.'s next confirmed earnings release is scheduled for October 23, 2026.

As of June 30, 2026, Hanall Biopharma Co., Ltd. has 50.78M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 19.54, and the price-to-book ratio stands at 19.61.

As of June 30, 2026, Hanall Biopharma Co., Ltd. trades at an EV/EBITDA multiple of 391.71 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 19.57 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 667.50 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 3.18T versus a market cap of 3.17T, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Hanall Biopharma Co., Ltd. maintains a current ratio of 1.49, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 27.84, indicating elevated leverage, while an interest coverage ratio of 9.12 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Hanall Biopharma Co., Ltd. posted a negative return on equity (ROE) of -15.68, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -11.55, reflecting losses generated across the asset base. The company generates approximately 515.15M in revenue per employee across its workforce of 315.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.95 indicates how many times Hanall Biopharma Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Hanall Biopharma Co., Ltd. recorded an income tax benefit of -2.84B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -27.75B and -24.90B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Hanall Biopharma Co., Ltd.'s stock has gained approximately 20.36% over the past 52 weeks. The 50-day moving average sits at 50,904.00, while the 200-day moving average is 51,861.75.

Over the twelve months ended June 30, 2026, Hanall Biopharma Co., Ltd. generated 162.66B in revenue and converted that into -24.90B in net income, yielding earnings per share of -488.98. EBITDA reached 8.13B, while operating income came in at 4.77B.

As of June 30, 2026, Hanall Biopharma Co., Ltd. holds 30.20B in cash and equivalents against 44.99B in total debt, resulting in a net debt position of 13.90B. Total book value stands at 161.63B, with working capital of 30.72B providing operational flexibility.

Hanall Biopharma Co., Ltd. produced -9.54B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -12.07B in capital expenditures, free cash flow totaled -21.60B - equivalent to -424.19 per share.

Over the twelve months ended June 30, 2026, Hanall Biopharma Co., Ltd. posted a gross margin of 52.76, reflecting its pricing power and cost economics. The operating margin of 2.93 and net profit margin of -15.31 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.68: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -1.44, meaning Hanall Biopharma Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Hanall Biopharma Co., Ltd.'s most recent stock split took place on May 24, 2006 with a 19:20 split ratio.

As of June 30, 2026, Hanall Biopharma Co., Ltd. has an Altman Z-Score of 25.28, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.